Sperm sequencing reveals extensive positive selection in the male germline 1

- Matthew DC Neville¹, Andrew RJ Lawson¹, Rashesh Sanghvi¹, Federico Abascal¹, My H Pham¹, Alex 2
- Cagan¹, Pantelis A Nicola¹, Tetvana Bavzetinova¹, Adrian Baez-Ortega¹, Kirsty Roberts¹, Stefanie V. 3
- Lensing^{1,2}, Sara Widaa², Raul E Alcantara^{1,3}, María Paz García⁴, Sam Wadge⁴, Michael R Stratton¹, 4
- Peter J Campbell¹, Kerrin Small⁴, Iñigo Martincorena¹, Matthew E Hurles¹, Raheleh Rahbari¹ 5
- 6 ¹Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Hinxton, United Kingdom
- 7 ²Sequencing Operations, Wellcome Sanger Institute, Hinxton, United Kingdom
- 8 ³Quotient Therapeutics Limited, Saffron Walden, UK
- 9 ⁴Kings College London, Department of Twin Research & Genetic Epidemiology, London, United Kingdom
- 10
- 11
- 12

Abstract 13

Mutations that occur in the cell lineages of sperm or eggs can be transmitted to offspring. In humans, 14 positive selection of driver mutations during spermatogenesis is known to increase the birth prevalence 15 16 of certain developmental disorders. Until recently, characterising the extent of this selection in sperm has been limited by the error rates of sequencing technologies. Using the duplex sequencing method 17 18 NanoSeq, we sequenced 81 bulk sperm samples from individuals aged 24 to 75 years. Our findings 19 revealed a linear accumulation of 1.67 (95% CI = 1.41-1.92) mutations per year per haploid genome, driven by two mutational signatures associated with human ageing. Deep targeted and exome NanoSeq 20 21 of sperm samples identified over 35,000 germline coding mutations. We detected 40 genes (31 novel) 22 under significant positive selection in the male germline, implicating both activating and loss-of-23 function mechanisms and diverse cellular pathways. Most positively selected genes are associated with 24 developmental or cancer predisposition disorders in children, while four genes that exhibit elevated 25 frequencies of protein-truncating variants in healthy populations. We find that positive selection during spermatogenesis drives a 2-3 fold elevated risk of known disease-causing mutations in sperm, resulting 26 27 in 3-5% of sperm from middle-aged to elderly individuals carrying a pathogenic mutation across the 28 exome. These findings shed light on the dynamics of germline mutations and highlight a broader 29 increased disease risk for children born to fathers of advanced age than previously appreciated.

30

32 Introduction

Human cells in all tissues accumulate mutations throughout life. In replicating tissues, acquired driver mutations that confer a selective advantage can promote the expansion of individual clones within competing stem and progenitor cell populations. While patterns of selection and clonal expansion have been extensively studied in cancers, recent research has also highlighted their occurrence in normal tissues during ageing¹⁻¹⁰.

38

39 The spermatogonial stem cells of the testis occupy a unique niche amongst other studied normal tissues. Among replicating cells, they have the lowest mutation rate, ~5-20 fold lower than any other studied 40 somatic cell type⁷. They are also the only replicating cells with the potential to transmit mutations to 41 offspring, balancing self-renewal and spermatogenesis to produce 150-275 million sperm per day post-42 puberty^{11,12}. Targeted sequencing studies have revealed that driver mutations are acquired in 43 spermatogonial stem cells and that these cell populations expand along seminiferous tubules, resulting 44 in elevated fractions of mutant clones that are detectable in sperm^{13–17}. Interestingly, all germline driver 45 46 mutations identified so far are activating missense hotspot mutations, which contrasts with a broader 47 range of activating and inactivating driver mutations observed in cancers and somatic tissues. These 48 germline driver mutations can have profound implications for offspring, as they are found in a set of 13 genes all known to cause severe developmental disorders¹⁸. This leads to a significant increase, up to 49 1,000-fold, in the sporadic birth prevalence of these disorders, with a strong correlation to elevated age 50 51 of the father¹⁹.

52

Technical limitations, related to the polyclonality and low mutation rate of testis and sperm, have 53 prevented extensive characterisation of this selection beyond a limited set of genes¹⁸. However, recent 54 advances in error-corrected duplex DNA sequencing approaches, in which information from both DNA 55 strands is used to detect mutations at single molecule resolution²⁰⁻²², have proven successful for the 56 accurate estimation of mutation burden in sperm^{23–25}. Here we combine the duplex approaches of whole 57 genome NanoSeq²³ with deep whole exome and targeted NanoSeq (Lawson A.R., Abascal F., P.A. 58 59 Nicola et al., manuscript submitted for publication) to characterise positive selection in the male 60 germline and quantify its consequences for accumulation of disease mutations in sperm.

61

62 **Results**

63 **Cohort and sequencing coverage**

64 We performed restriction enzyme based, whole genome NanoSeq²³ of bulk semen samples (n = 81; 1-

2 timepoints per donor; age range: 24-75 years) and matched blood (n = 119; 1-3 timepoints; age range:

66 22-83 years) from 63 men in the TwinsUK cohort²⁶ (including 9 monozygotic and 3 dizygotic twin

pairs; Methods; Supplementary Table 1). The analysed sperm samples had sperm counts above 1

68 million/mL, as those below this threshold showed evidence of somatic cell contamination 69 (Extended Data Fig. 1; Supplementary Note 1). Across these samples, the mean number of unique 70 DNA molecules per site where a mutation was callable (duplex coverage - dx) was 3.7dx in sperm, and 71 4.3dx in blood (Extended Data Fig. 2a). For sperm, a haploid cell, 1dx is equivalent to one cell, 72 whereas for blood, a diploid cell, 2dx is equivalent to one cell.

73

Mutational burden and signatures 74

75 We performed stringent variant filtering of single nucleotide variants (SNVs) and small insertion-76 deletion mutations (indels) from sperm and blood whole genome NanoSeq (Methods). From the 6,653 SNVs detected in sperm, we estimated an age-related accumulation of 1.67 substitutions per vear per 77 haploid genome (95% CI 1.41-1.92, linear mixed-effect regression). This is comparable to estimates 78 from paternal *de novo* mutations (DNMs) in family pedigrees²⁷ of 1.44 substitutions per year (95% CI 79 1.00-1.87) and seminiferous tubules of the testes⁷ of 1.40 substitutions per year (95% CI 1.02-1.76; 80 Fig. 1a). Indels accumulated in sperm at a rate of 0.10 indels per year per haploid genome (95% CI 0.06-81 0.15), similar to the rate observed in paternally phased DNMs²⁷ of 0.08 haploid indels per year (95%) 82 CI -0.02-0.17) and seminiferous tubules of the testes⁷ of 0.08 haploid indels per year (95% CI 0.02-83 84 0.13; Fig. 1b).

85

86 From the 92.035 SNVs and 4.641 indels detected in whole blood, we estimated an age-related 87 accumulation of 19.9 substitutions per year per diploid genome (95% CI 17.3-22.5; Fig. 1c) and 0.9 88 indels per year (95% CI 0.7-1.1; Fig. 1d). Both estimates are within the range of mutation rates observed 89 for specific cell types in the blood⁸, consistent with measuring a weighted average of these cell types in 90 whole blood (Extended Data Fig. 3a,b). We find that individuals had a mean of 7.6-fold more 91 substitutions per bp per year (range 4.2-11.5; Fig. 1e) and 6.3-fold more indels per bp per year (range 92 2.2-18.7; Fig. 1e) in blood than in sperm. Accounting for twin status or multiple timepoints from the 93 same individuals had a significant predictive effect for mutation burden in blood but not in sperm 94 (Supplementary Note 2).

95

96 The SNV mutational signatures in sperm were inferred to be SBS1 (mean 16%) and SBS5 (mean 84%), the expected clock-like ageing signatures²⁸ (Fig. 1f-g). In blood, SBS1 (mean 15%) and SBS5 (mean 97 75%) were also the main mutational signatures, with an additional contribution of SBS19 (mean 10%), 98 which has been linked to persistent DNA lesions in hematopoietic stem cells²⁸ (Fig. 1f-g). We observed 99 that all signatures were correlated with age (Extended Data Fig. 3c,d). SBS1 and SBS5 accumulated 100 101 in individuals at a mean of 8.9-fold (range 2.3-39.1) and 6.8-fold (range 3.7-10.9) higher rate in blood 102 than in sperm respectively (Extended Data Fig. 3e), indicating that SBS19 does not explain a 103 substantial fraction of the mutation burden gap between the two tissues.



104

105 Figure 1 | Mutational burden and signature analysis in sperm and matched blood

a,b, Substitutions (**a**) and indels (**b**) per haploid cell from sperm whole genome NanoSeq, trio paternal DNMs²⁷ 106 107 called with standard sequencing and clonal variants from seminiferous tubules of testis⁷ called with standard 108 sequencing. Dots indicate single donors while boxplots for testis variants show 1-15 samples per donor. c.d. 109 Substitutions (c) and indels (d) per diploid cell for different ages from blood NanoSeq samples. e, Ratio blood to 110 sperm substitutions and indels per diploid cell per vear. Each dot corresponds to an individual with both a blood 111 and sperm sample and where individuals had multiple timepoints the mean value of all timepoints in that tissue 112 was used. f, Trinucleotide mutation counts in all sperm and blood samples. g, Contribution of signatures SBS1, 113 SBS5, and SBS19 in sperm and blood samples ordered by age. a,b,c,d, Models are linear mixed regressions with 114 95% CIs calculated by parametric bootstrapping. a,b,e, Box plots show the interquartile range, median, and 95% 115 confidence interval for the median.

116

Selective pressure dynamics in sperm 117

To investigate positive selection in protein-coding regions in sperm we required much greater duplex 118

- coverage. Therefore, we utilised a capture-based modification to NanoSeq (Lawson A.R., Abascal F., 119
- P.A. Nicola et al., manuscript submitted for publication) to deeply sequence coding regions from the 120

121 same set of semen samples. Specifically, we sequenced 38 samples using whole-exome NanoSeq to a 122 mean depth of 551dx per sample (20.923 cumulative dx), and 81 samples using targeted NanoSeq to a 123 mean depth of 985dx per sample (79,811 cumulative dx) with a target panel consisting of 263 canonical 124 cancer driver genes, 107 of which are also associated with developmental disorders (Extended Data 125 Fig. 2a; Supplementary Table 2; Methods). After variant filtering (Methods), we detected 56,503 126 (58% within coding regions) SNV/indel mutations from the exome panel and 5.059 (58% within coding 127 regions) from the targeted cancer panel. The age correlation of mutation burden for exome and targeted sample sets were consistent with whole genome NanoSeq after correcting for the relative trinucleotide 128 129 composition of sequencing coverage (Extended Data Fig. 2b).

130

The vast majority of variants (99.5%) were detected only in a single duplex molecule of a sample. 131 Similarly, in the 23 samples with two timepoints (mean 12.1 year gap), 99.3% of the 5,143 variant calls 132 133 from the first timepoint were not called in the second timepoint. These results are consistent with sperm 134 being a highly polyclonal collection of cells derived from a large population of spermatogonial stem

- 135 cell progenitors in the testis.
- 136

The exome-wide strength of positive selection in sperm was quantified by estimating the rate of non-137 138 synonymous (N) relative to selectively neutral synonymous (S) mutations (dN/dS ratio, where dN/dS =139 1.0 indicates neutrality). We employed the dNdScv algorithm, which by default calculates dN/dS while 140 adjusting for trinucleotide context and several gene-level genomic covariates that influence mutation 141 rate²⁹. We modified this algorithm in three ways: first, we adjusted for duplex sequencing coverage per 142 base to correct for differential coverage within and between genes; second, we incorporated an 143 adjustment for CpG methylation levels in the testis due to its significant influence on mutation rates; 144 and third, we switched from trinucleotide to pentanucleotide context to better account for the effects of extended contexts on germline mutation rates³⁰. These modifications refined exome-wide dN/dS ratios 145 by resolving specific mutation rate biases but had minor effects on gene-level dN/dS ratios 146 147 (Extended Data Fig. 4, Supplementary Note 3).

148

149 Using this model, we estimated the dN/dS ratio in the exome-sequenced samples to be 1.07 (95% CI 1.04-1.10). This ratio implies that 6.5% (95% CI 3.8%-9.1%) of the observed non-synonymous 150 151 substitutions in sperm conferred a clonal advantage during spermatogenesis in this cohort. Splitting the 152 cohort into thirds by age, we find that the exome-wide dN/dS ratio increased with age. The ratio was 1.01 (95% CI 0.93-1.09) in 26-42 year olds, 1.03 (95% CI 0.97-1.10) in 43-58 year olds, and 1.09 (95% 153 154 CI 1.06-1.13) in 59-74 year olds (Fig. 2f). This suggests that the dN/dS ratio increases over male 155 lifespan and that the cohort wide dN/dS ratios presented here in part reflect the age distribution of

156 samples (age range 26-74; mean 53 years).

157

We next compared the dN/dS ratios across gene sets related to spermatogenesis expression³¹ (Fig. 2g). 158

We find that the gene sets with the highest dN/dS ratios are those which are highly expressed during 159

160 spermatogenesis (1.25, 95% CI 1.13-1.38) and most specific to differentiated spermatogonial stem cells

(1.11, 95% CI 1.05-1.17). In contrast, the genes which are unexpressed in spermatogenesis (0.98, 95% 161

162 CI 0.88-1.11) and the genes most specific to elongating spermatids (1.01, 95% CI 0.94-1.08) show

dN/dS ratios close to neutrality. These results are consistent with the understanding that excess 163

nonsynonymous mutations observed in sperm confer a competitive advantage earlier in their cell 164

lineage, specifically in the spermatogonial stem cells of the testis¹⁵. 165

166

Discovery of novel genes and pathways under positive selection in the germline 167

168 We then investigated which genes were driving the signal of positive selection using the combination 169 of the exome and targeted panel datasets (Methods). We applied dN/dS tests for excess non-170 synonymous mutations at both the gene-wide and SNV hotspot levels, which together identified 40 171 genes under significant positive selection. Of these, 35 genes reached exome wide significance at the 172 gene level (FDR q < 0.1; Supplementary Table 3) and/or contained one of 17 exome-wide significant hotspots (q < 0.1; Extended Data Table 1). The genes *PTPN11*, *MIB1*, *RIT1*, *FGFR3*, *EP300*, and 173 174 FGFR2, were significant in both the gene and hotspot tests, KDM5B, NF1, SMAD6, CUL3, RASA2, 175 PRRC2A, PTEN, ROBOI, DDX3X, CSNK2B, KRAS, PPMID, ARIDIA, BRAF, HRAS, KMT2E, SCAF4, BMPR2, TCF12, CCAR2, DHX9, NSD1, LZTR1, ARHGAP35, CBL, SSX1, and RBM12 were 176 177 significant in only the gene test, and SMAD4 and FAM222B were significant in only the hotspot test (Fig. 2a,b). We excluded the major seminal fluid component gene *SEMG1* from this list, despite excess 178 179 indels driving gene-level significance. This gene is expressed at extremely high levels in seminal vesicles and unexpressed during spermatogenesis³⁶, suggesting that the enrichment may be the result of 180 a known process of indel hypermutation in highly-expressed genes^{37,38} from a small contamination of 181 182 seminal vesicle DNA, rather than selection in germ cells.

183

184 Subsequently, we carried out restricted hypothesis dN/dS tests at the per-gene and per-site level. The 185 gene level test examined only the set of 263 canonical cancer driver genes on our target panel and the site level test used a set of 1.963 sites composed of known cancer hotspots and recurrent DNM sites 186 from the DDD cohort³⁹. This identified 5 additional genes: *KDM5C*, *KMT2D*, *AR*, *CTNNB1*, and *RAF1* 187 188 and 7 hotspots not already significant at the exome wide level (q < 0.1; Fig. 2a,b; 189 Supplementary Table 4; Extended Data Table 1).



191 Figure 2 | Germline positive selection

192 **a,b,c** Genes with significant dN/dS ratios from exome-wide and restricted hypothesis tests. **a,** Mutation count split 193 by mutation class. **b**, Enrichment over expectation of mutation classes. **c**, Mutation type driving dN/dS enrichment, 194 COSMIC³² cancer gene tier, developmental disorder gene link in DDG2P³³, and potential germline selection geneset. d.e. Observed sperm mutations across the cohort for CUL3 and SMAD4 where the height of the "lollipop" 195 196 represents the number of unique samples with a mutation at that location and the colour represents its mutation

197 type. Mutations are labelled with their amino acid consequence for point substitutions or their insertion 198 (ins)/deletion (del) consequence of in frame (IF) or frameshift (FS). A "P" indicates that the variant is classified 199 as pathogenic/likely pathogenic in ClinVar³⁴. Exons are shown as purple rectangles and the blue background 200 represents the total duplex coverage across the cohort. Lines below the gene indicate COSMIC somatic mutations in cancer within that gene³², **f-h**, dN/dS ratios for sperm SNVs across sets of individuals or genes, where the dotted 201 202 black line indicates neutrality and the dotted orange line represents the cohort average across all genes. f. Exome-203 wide dN/dS ratios in sperm for the cohort split into thirds by age. g, Expression gene sets from single-cell 204 sequencing of germ cells³¹. Expression levels represent 7 bins of mean expression levels across germ cell stages 205 and expression clusters represent genes most characteristic to certain germ cell stages. Germ cell types include 206 undifferentiated and differentiated spermatogonial stem cells (SSCs), spermatocytes, round spermatids (1) and 207 elongating spermatids (2). h, Germline selection genes and cancer gene census genes split by ten canonical cancer pathways in KEGG³⁵. i, The observed/expected mutation rate in sperm for bins of mutations. COSMIC and DDD 208 209 are bins of variants that have been seen at different levels of recurrence. Error bars depict 95% CIs.

- 210
- 211

212 Genes linked to germline positive selection to date all operate through activating missense mutations, with 12 linked to the RAS-MAPK signalling pathway¹⁸ and one (*SMAD4*) linked to TGF- β /BMP 213 signalling⁴⁰. Our findings replicate *SMAD4* and 8 of the 12 RAS-MAPK pathway genes as under 214 215 significant positive selection in this dataset. The 4 genes which did not reach significance (MAP2K1, 216 MAP2K2, SOS1, and RET) each had between 2- and 4-fold enrichment of missense mutations, which 217 corresponded to nominally significant missense enrichment in all 4 genes (p < 0.1). Given the direct 218 evidence for these genes driving clonal selection in testis and nominal enrichment from sperm 219 sequencing, we expect that each will reach exome-wide significance with deeper sequencing.

220

We estimate that together, the 44 genes linked to germline selection here or in previous studies, contain 221 222 an estimated 357 (95% CI: 319–387) excess non-synonymous variants in exome sequenced samples. This would account for 23% (95% CI: 14%–43%) of the total estimated driver variants across the 223 224 exome. The wide confidence intervals and the sensitivity of this estimate to the mutation model used 225 (Supplementary Note 3) suggest that small uncertainties in mutation rates, when propagated across the 226 exome, make it difficult to precisely estimate the fraction of drivers explained. Nevertheless, the 227 findings suggest that additional driver genes remain to be discovered.

228

229 The 31 newly identified genes demonstrate that germline positive selection is not restricted to activating mutations or to the RAS-MAPK pathway. For instance, 30/31 of the novel genes are enriched for loss-230 function mutations such as nonsense, splice, and indel variants, suggestive of protein-inactivating 231 mechanisms of selection (Fig. 2c,d). Splitting the germline selection genes and known cancer genes by 232 ten canonical cancer pathways within the Kyoto Encyclopedia of Genes and Genomes (KEGG)³⁵, we 233 234 find that the top gene groups enriched in dN/dS are RAS-MAPK, Wnt and TGF- β /BMP signalling

235 (Fig. 2h). Indeed, many of the novel selection genes are linked to the RAS-MAPK pathway, such as

236 *NF1*, *CUL3* and *LZTR1*, Wnt signalling (i.e. *CSNK2B*, *MIB1*, *CCAR2*), and TGF-β/BMP signalling (i.e.

237 SMAD6, TCF12, BMPR2) (Fig. 2c). We also identified a number of genes that encode epigenetic

238 modifiers (i.e. KDM5B, KDM5C, ARID1A, KMT2D, KMT2E, EP300, NSD1), and genes encoding RNA

239 metabolism proteins (i.e. DHX9, DDX3X, SCAF4). These findings highlight a new diversity of genes,

240 mutational mechanisms, and pathways driving germline selection, however future work will be needed

241 to confirm the specific pathways and roles through which these genes drive clonal expansion during

- 242 spermatogenesis.
- 243

244 It has been observed that cancers and germline developmental disorders share causal pathways and 245 genes^{41–44}. Notably, the 13 genes previously linked to germline positive selection are all known cancer and known developmental disorders genes^{18,40}. This pattern holds, but to a lesser extent, in the new 246 germline selection genes identified here: 16 of 31 genes are tier 1 or 2 cancer census genes³² and 24 of 247 31 are linked to monogenic developmental disorders in the DDG2P database³³ (Fig. 2c; 248 249 Supplementary Table 5). Among the positively selected genes which are not associated with monogenic developmental disorders, three are linked to other monogenic disorders⁴⁵ (Fig. 2c; 250 Supplementary Table 5). These include *BMPR2* associated with pulmonary arterial hypertension^{46–48}, 251 *ROBO1* associated with pituitary stalk interruption syndrome^{49,50} and *SSX1* associated with X-linked 252 253 spermatogenic failure⁵¹.

254

255 The overlap between germline positive selection genes and cancer/developmental disorders is also 256 apparent at the variant level. Somatic mutations that are most frequently observed (>50 times) in the COSMIC cancer database are enriched 11-fold (95% CI: 6-20) among our sperm mutation dataset after 257 258 adjusting for expected mutation rate (Methods). Similarly, germline mutations that are most frequently observed (>5 times) in a large cohort of children with developmental disorders are enriched 66-fold 259 260 (95% CI: 41-100) in our sperm mutation dataset (Fig. 2i). In addition, the mutation types (e.g. missense 261 or protein truncating variants) enriched in sperm for a given gene are largely consistent with those 262 enriched in cancer and those causal for developmental disorders (Extended Data Fig. 5a-c). These 263 results show a clear overlap between genes, hotspots, and mutation mechanisms which drive germline 264 positive selection, cancer, and developmental disorders. A notable exception to this pattern is SMAD4, 265 which has two distinct missense hotspots in sperm that are developmental disorder hotspots causal for Myhre syndrome⁵² but that are not often seen in cancers, replicating recent findings⁴⁰ (Fig. 2e). 266

267

Positive selection drives enrichment of disease-causing mutations in sperm 268

269 Given the association of many positively selected genes to disease, it is of interest to assess to what 270 degree germline positive selection may increase the fraction of sperm carrying potential disease-causing

271 mutations, and thus the birth prevalence of the associated disease. To estimate the fraction of sperm 272 carrying specific classes of variants, we aggregated the variant allele frequencies (VAFs) of different 273 mutation types and compared this to expected values. Expected values were generated using the custom 274 fit dNdScv mutation model (adjusted for base pair coverage, CpG methylation, and trinucleotide 275 context) and normalised to account for the linear impact of age on mutation rate (Methods).

276

277 We find that the fraction of sperm carrying a non-coding or synonymous mutation increases linearly with age as predicted by the model (Extended Data Fig. 6). In contrast, the frequency of missense, 278 truncating (nonsense and splice) variants, and coding indels deviate above expected values in older 279 280 individuals, consistent with dN/dS results and indicative of positive selection acting over time 281 (Extended Data Fig. 6).

282

We then generated a list of likely monoallelic disease-causing mutations, which includes ClinVar³⁴ 283 pathogenic/likely pathogenic variants and highly damaging variants in high confidence monoallelic 284 developmental disorder genes from DDG2P³³ (loss-of-function or missense CADD⁵³ score >30). This 285 list represents a conservative estimate of disease-causing mutations due to the incomplete discovery and 286 287 annotation of disease-causing variants and genes. We found that the observed fraction of sperm 288 containing disease mutations was markedly higher than that expected under a germline mutational 289 model at all ages of our cohort. The expected fraction of sperm with a likely disease mutation ranged 290 from 0.73% in 30-year-olds to 1.6% in 70 year olds, whereas, fitting a quasibinomial regression, the 291 observed fraction of sperm with a likely disease mutation in each age bracket ranged from 2% (95% CI: 292 1.6%-2.5%) in 30-year-olds to 4.5% (95% CI: 3.9%-5.2%) in 70 year olds (Fig. 3c). These differences 293 represent similar enrichments of 2.8-fold (95% CI: 2.2 to 3.5) and 2.9-fold (95% CI: 2.5 to 3.3) in 30-294 year-olds and 70-year-olds respectively.

295

296 Interestingly, the disease cell fraction estimates are made up of many low frequency variants rather than 297 being driven by individual high VAF mutations. The estimates in exome samples are made up of a mean 298 of 18.3 unique variants (range 4-62) per individual. Furthermore, 692 of 696 (99.4%) of all those 299 variants are only observed in a single sperm cell, similar to the average of all variants (99.5%).

300

301 We next investigated to what degree the observed enrichment of disease mutations can be attributed to 302 driver mutations in positively selected genes. Fitting a quasibinomial regression, we observe a strong 303 positive correlation between age and driver rate (P = 7.95e-06) with an estimated 0.5% (95% CI: 0.3%-304 0.8%) of sperm from individuals at age 30 and 2.6% (95% CI: 2.0%-3.3%) of sperm from individuals 305 aged 70 carrying a known driver mutation (Fig. 3b). However only about two thirds (65.6%) of those

306 driver mutations meet our criteria of likely disease-causing.





307

308 Figure 3 | Pathogenic burden

309 a, Estimated mean percentage of sperm in the cohort carrying a likely monoallelic disease mutation (Left) or a 310 driver mutation in a germline selection gene (Right). Disease mutations are divided into the fraction that was 311 expected from the mutation model, the portion explained by driver variants and the portion unexplained. Driver 312 mutations are split by those contributing to the disease mutations and the remainder, 'Ageing drivers'. **b**, 313 Estimated percentage of sperm per individual carrying a driver mutation by age. c, Observed and expected 314 percentages of sperm with likely disease mutation by age. b,c, Model fits represent quasibinomial regressions 315 with 95% confidence intervals. d, Cohort means from (a) split by gene and ordered by estimated mutation 316 percentage. Per-gene contributions are shown above each gene: the summed contributions of all genes are 317 shown below. Genes with 4 or fewer variants are grouped on the left with a condensed x-axis for clarity. 318

319 Mutations in sperm that are likely disease-causing and those that are known driver mutations therefore 320 represent overlapping but distinct annotations (Fig. 3a). Across the cohort, an estimated 3.3% of sperm carry a likely disease-causing mutation. Of this, approximately one-third (1.2%) is expected by the 321 322 neutral mutation model, another third (1.1%) is explained by known driver mutations, and the remaining third (1.0%) is unexplained by either source. These findings suggest that the increase in likely disease-323 324 causing mutations is largely driven by germline positive selection, but also indicate that additional 325 driver genes with disease associations remain to be identified.

326

327 Examining driver mutations which do not meet our criteria of a likely disease-causing mutation, we 328 find that they impact an estimated 0.6% of sperm across the cohort. The consequences of these 329 mutations are unclear. For instance, driver variants in SMAD6, which has a variably penetrant link to

congenital phenotypes⁵⁴, may be disease-causing in some cases but not others. Other potential 330 331 consequences include mutations that are disease-causing but not vet annotated as such, less able to 332 fertilise an egg, embryonic lethal, or biallelic disease-causing.

333

Much of the fraction of sperm with a disease and/or a driver mutation can be attributed to a small number 334 335 of genes in the exome. From 374 genes with at least one such variant, the 33 genes with >5 independent mutations, most of which are under significant positive selection (26/33), represent 42.8% of the 336 337 disease/selection fraction in sperm (Fig. 3d). Strikingly, 6 of those genes, all of which are under significant positive selection, (KDM5B, MIB1, SMAD6, PRRC2A, NF1, and PTPN11) together explain 338 339 over 20% of the disease/selection fraction. This suggests that although individual mutations we observe 340 are at low frequencies, positive selection systematically favours the likelihood of observing variants in 341 driver genes.

342

343 We next sought to examine whether there are risk factors other than age which contribute to the accumulation disease or driver mutations in sperm. Currently known mutagenic effects in the male 344 germline include chemotherapy and inherited DNA repair defects^{39,55} and small effect size influences 345 of genetic ancestry and smoking⁵⁶. While the cohort did not include any individuals with known 346 347 chemotherapy treatments or DNA repair defects, phenotype data was available for BMI, smoking, and 348 alcohol consumption, all of which have some evidence of driving mutation burden or driver mutation 349 rate in some somatic tissues⁵⁷. We used multivariate generalised linear models to test the association between these factors and measures of mutation burden, signatures, and driver cell fractions, correcting 350 351 for multiple testing (Methods; Extended Data Fig. 6). Regardless of the sperm sequencing set examined (targeted, exome, or whole genome) only age was significantly correlated with measures of 352 353 mutational burden, signatures, and driver cell fractions. No significant effects were found for BMI, 354 smoking pack-years, or alcohol drink-years. However, in blood samples, age, smoking, and alcohol 355 consumption showed significant effects on SNV and SBS5 burdens. These results suggest that, unlike 356 many somatic tissues, the male germline mutation landscape may be largely protected from these risk 357 factors, although larger cohorts will be needed to interrogate possible small effect sizes.

358

359 Selection in germ cells relative to single generation and population-level variants

Mutations in sperm account for ~80% of DNMs and are therefore also the origin of most population 360 361 level variants. Comparisons between these different sources of germline variants provide an opportunity 362 to explore how positive selection in the male germline may manifest over time.

363

Examining control DNMs from offspring without clinical phenotypes⁵⁸ we found a dN/dS ratio 364 365 consistent with neutrality of 0.98 (95% CI 0.90-1.08; Fig. 4a). In contrast, the dN/dS ratio in DNMs

366 from offspring with developmental disorders showed a large enrichment of nonsynonymous variants, as previously reported³⁹: 1.36 (95% CI 1.33-1.39; Fig. 4a). However, ascertainment biases in these 367 cohorts suggest that these dN/dS ratios may not accurately reflect the dN/dS ratio of DNMs entering 368 369 the population. Future large DNM studies of birth cohorts will likely be required to give less biased 370 estimates.



371

372 Figure 4 | Comparison to population variation

a, Exome-wide dN/dS ratios across different variant sets, including sperm variants from all exome sequenced 373

samples, de novo mutations (DNMs) from a collection of healthy trios⁵⁸ and the Deciphering Developmental 374

Disorders (DDD) cohort³⁹; and population variants from $gnomAD^{59}$ split by allele frequency (AF). **b**, 375

376 Observed/expected enrichment of missense and loss-of-function (LOF; essential splice, nonsense, indel) variants

377 in positively selected genes within sperm (x-axis) from dN/dS models vs gnomAD LOF z-score. Positive z-

378 scores indicate LOF depletion, while negative ones indicate excess over expected. Error bars indicate 95% CIs.

379

380 The pattern of largely neutral dN/dS ratios in control DNMs contrasts with the strong evidence of

negative selection in human single nucleotide polymorphisms (SNPs), particularly in common SNPs. 381

382 To shed light on this, we calculated dN/dS ratios for population variants at different allele frequencies

(AF) in the population using data from $gnomAD^{59}$ (Fig. 4a). This revealed a decay in dN/dS ratios for 383

384 population variants with higher AFs, a pattern consistent with purifying selection operating over many

generations on germline SNPs. Altogether, these analyses suggest that the dominant selection force on germline mutations is positive selection during spermatogenesis but negative selection between generations. This dynamic mirrors the well-established contrast between selective forces on cancer mutations and those on germline mutations in populations²⁹.

389

390 We then compared the per-gene enrichment of loss-of-function mutations in sperm to those of 391 population germline variants using the gnomAD loss-of-function z-score. This z-score is a measure of 392 how significantly the observed counts differ from expectations of a germline mutation model. The vast 393 majority of genes in gnomAD have a positive z-score, indicative of depletion of LOFs and the negative 394 selection expected in populations. Of the 31 significant germline selection genes with LOF enrichment 395 in sperm (range 3-fold to 50-fold), 27 were depleted for LOFs in gnomAD. Each of these genes has a 396 disease phenotype, consistent with a model by which these genes are selected for in spermatogenesis 397 but purged from the population by strong negative selection. Interestingly, 4 significant germline 398 selection genes had more loss-of-function mutations than expected in gnomAD: SMAD6. MIB1. LZTR1. 399 and SSX1 (Fig. 4b). The latter 3 of these genes are 3 of the 4 strongest outliers of LOF enrichment of 400 all genes in gnomAD v2 and were given a cautionary outlier label for unexplained LOF enrichment. 401 Our results suggest that the explanation behind their apparent enrichment in gnomAD is that germline 402 positive selection introduces them at a higher rate than for other genes and negative selection against 403 these variants is not strong enough to mask it. 404 405

406

Discussion 408

We sequenced sperm and blood from healthy men spanning a wide age range to quantify mutation rate 409 and positive selection in the male germline. The observed mutation rates and mutational signatures in 410 sperm were consistent with those from family trio and testis sequencing studies^{7,27,60–63}. We find that, 411 despite sharing the same mutational signatures, SBS1 and SBS5, mutations accumulate at 412 413 approximately an 8-fold lower rate in sperm compared to blood. This supports our previous observations comparing germline mutations in testes to a wide range of somatic tissues⁷ and emphasises the protected 414 415 nature of the germline relative to the soma.

416

417 Analysing over 35,000 coding variants from sperm exome-wide, we build on the 13 previously 418 identified germline selection genes, identifying an additional 31 genes under positive selection. This 419 provides a foundational catalogue of genes under selection in the male germline and expands the 420 diversity of pathways and mutational mechanisms linked to selection in this tissue.

421

422 Our findings have significant implications for studies relying on germline mutation models, as they do 423 not currently account for germline positive selection. As shown here, this can lead to inaccurate 424 constraint metrics in population cohorts. Importantly, this bias can also affect the identification of novel 425 disease-causing genes from DNM enrichment tests. For instance, the recent identification of an excess of *de novo* loss-of-function mutations in $MIB1^{39}$ likely reflects germline selection rather than disease 426 427 association. Loss-of-function variants in *MIB1* are more common in population cohorts than expected for a gene associated with developmental disorders, and carrying one of these variants does not correlate 428 with developmental disorder phenotypes⁶⁴. In principle, adopting case-control tests for DNM 429 430 enrichment should help to exclude genes under germline selection that are not linked to the disease. However, sufficiently large control trio datasets, as well as close age matching of controls to account 431 432 for the age dependency of germline selection, will be needed to ensure sufficient statistical power. Until 433 such resources become available, analyses of DNM enrichment in disease should take into account the 434 evidence for germline selection influencing individual genes presented here (Supplementary Table 3). 435

436 Unlike the example of *MIB1*, most genes under positive selection during spermatogenesis are known to be associated with severe monogenic disorders with mutation mechanisms under positive selection 437 matching those associated with disease. We demonstrate that this positive selection leads to a striking 438 439 2-3 fold enrichment in the fraction of sperm carrying a likely disease mutation across the age range 440 studied. As a result, we estimate that 3-4% of sperm from men over 50 carry a likely disease-causing mutation. Somewhat reassuringly, we note that typical paternal ages at conception are younger than the 441 average age of sperm donors studied here, and that the impact of germline positive selection will be 442

443 correspondingly weaker. Future investigations, including sequencing of sperm from cohorts focused on
 444 men under the age of 30 will aid in developing estimates of germline selection strength in this age range.
 445

A key consideration when interpreting the fraction of disease mutations in sperm is that this fraction may not directly correspond to the rate at which these variants are observed in live births. There are a number of reasons why, for some genes, the transmission rate to live births could be lower than those observed in sperm, including impaired ability of sperm to fertilise an egg, embryonic lethality, or increased pregnancy loss (**Supplementary Note 4**). Future studies, such as sequencing of trio DNMs from large birth cohorts, will be needed to quantify the relationship between the rate of positively selected disease mutations in sperm and disease incidence in populations.

453

454 While up to 3-5% of sperm in middle-aged to elderly individuals harbouring a known driver mutation 455 has a large impact on offspring disease risk, it is on the low end of the spectrum of estimates in 456 proliferative somatic tissues. For instance, in comparable age groups, more than 40% of cells in endometrial and esophageal epithelium carry a driver mutation^{2,5}, whereas only a few percent of cells 457 are estimated to carry a driver mutation in healthy colon or liver^{3,4}. For blood, on average only a few 458 percent of cells carry a driver mutation in middle aged individuals, but some individuals can present 459 460 large clonal expansions due lack of severe spatial constraints for clonal expansion⁹. While the germline 461 mutation rate is under evolutionary pressure to remain low to prevent detrimental mutations across the genome, it is perhaps under particularly strong pressure to keep driver mutation rate low, as a single 462 463 germline driver mutation can cause disease in offspring. It is likely that the tubular organisation of the testis provides strong spatial constraints to prevent large clonal expansions, limiting the accumulation 464 465 of driver mutations in sperm despite the large number of cell divisions required to sustain sperm production. The low relative rate of driver mutations in the male germline is also consistent with the 466 unique aspects of spermatocytic tumours, the tumour type thought to derive from spermatogonial stem 467 cells in the testis. Spermatocytic tumours are rare relative to most somatic tumours and are primarily 468 driven by chromosome aneuploidies⁶⁵ rather than the classical sequential acquisition of driver mutations 469 leading to cancer transformation^{66,67} observed in driver rich somatic tissues. 470

471

472 The findings of this study provide important insights into the historically underexplored reproductive 473 ageing risks associated with the male germline. This contrasts with the well-established relationship 474 between maternal ageing and reproductive risks, where decreasing oocyte quality with age leads to increased rates of pregnancy loss and aneuploidy⁶⁸. Our results demonstrate that driver mutation 475 476 accumulation from the male germline's continuous cell proliferation is a substantial risk, though one spread across many genes. As trends toward delayed reproduction continue⁶⁹, it is essential to recognise 477 478 that both paternal and maternal ageing contribute to elevated risks for offspring, albeit primarily through 479 different biological mechanisms. Future research will refine our understanding of selective pressures

- and disease risk associated with germline mutation, enhancing our understanding of their implications
- for human reproduction and health.

It is made available under a

Extended Figures 485



486

487 **Extended Data Fig. 1 | Sperm counting**

488 **a**,**b**,**c**, Slides of Papanicolaou stained semen samples for (a) an azoospermic sample where no sperm cells are 489 visible, (b) an oligozoospermic sample where a small number of sperm samples are visible and (c) a 490 normozoospermic sample where many sperm cells are visible. Sperm concentrations are given for each sample 491 in millions of sperm per ml (M/ml). The black band in the bottom left of each slide photo corresponds to 492 $100\mu m$. d, The distribution of sperm counts on a log scale among semen samples analysed with colour bands 493 indicating the concentration bin of the sample. All samples below 1 million/mL were subsequently excluded. e, 494 The distributions of mutation burden per year from blood samples and three categories of sperm samples broken 495 down by sperm concentration.





497

498 Extended Data Fig. 2 | Coverage summary

499 a, Mean duplex coverage (log scale) and percentage of genome covered (log scale) per sample. Panels 500 summarise the mean duplex coverage (dx) and mean percentage of genome covered per NanoSeq type and 501 tissue. b, Mutation burden of targeted (dark orange), exome (yellow), and genome (blue) sperm sequenced 502 samples that are observed without correction (left), corrected for trinucleotide composition of covered base pairs 503 relative to the whole genome (middle) or corrected and masked for mutations and coverage in the 44 genes 504 linked to germline positive selection (right). Model fits are linear regressions with 95% CI bands.



505

506 Extended Data Fig. 3 | Mutation rates relative to blood cell types and split by signatures

507 **a,b**, Substitutions (**a**) and indels (**b**) per diploid cell from blood NanoSeq relative to specific blood cell types⁸.

- 508 c,d, Substitutions per haploid cell for sperm (c) and diploid cell for blood (d) split by signature contributions of 509 SBS1, SBS5, and SBS19. a,b,c,d, Models are linear mixed regressions with 95% CIs calculated by parametric
- 510 bootstrapping. e, Ratio of age-corrected blood to sperm substitutions per diploid cell per year for mutations
- 511 assigned to SBS1 and SBS5. Each dot corresponds to an individual with both a blood and sperm sample and
- 512 where individuals had multiple timepoints the mean value of all timepoints in that tissue was used. Box plots
- 513 show the interquartile range, median, and 95% confidence interval for the median. f, Distribution of indel types
- 514 observed in sperm and blood.





515

Extended Data Fig. 4 | Model selection dN/dS 516

517 a,b, Mean duplex coverage (a) and methylation percentage (b) of all base pairs with exome sequencing 518 coverage split by mutation consequence. c, C>T mutation rate at CpG sites in exome sequenced samples split by 519 methylation bin based on percentage methylated from testis bisulfite sequencing⁷⁰. **d**, Comparison of global 520 dN/dS values from exome sequenced samples using different modifications to the dNdScv algorithm. Categories 521 are all nonsynonymous mutations, missense, nonsense or essential splice. The basic model excludes genes 522 which have no coverage but otherwise uses default parameters. Additional models show the impact of adding 523 corrections for duplex coverage per base pair (BasePairCov), CpG methylation level (CpGmeth), and 524 pentanucleotide context (Penta). e, Comparison of per-gene significance in exome-wide (blue) or restricted 525 hypothesis (orange) dN/dS tests using the different models. Genes that did not reach significance in either test 526 are shown in grey. Error bars indicate 95% CIs.



528

529 Extended Data Fig. 5 | Gene mutation mechanisms

530 a, The mutation mechanism assigned to each gene based on the mutation pattern in sperm, developmental 531 disorders and cancer (Methods). b,c,d,e,f,g, Observed sperm mutations across the cohort for six illustrative

532 genes where the height of the "lollipop" represents the number of unique samples with a mutation at that

- 533 location and the colour represents its mutation type. Mutations are labelled with their amino acid consequence
- 534 for point substitutions or their insertion (ins)/deletion (del) consequence of in frame (IF) or frameshift (FS). A
- "P" indicates that the variant is classified as pathogenic/likely pathogenic in ClinVar³⁴. Exons are shown as 535
- purple rectangles and the blue background represents the total duplex coverage across the cohort. Lines below 536
- the gene indicate COSMIC somatic mutations in cancer within that $gene^{32}$. 537



538

Age (years)

539 Extended Data Fig. 6 | Mean variant class count per individual by age

540 The relationship between age and the mean count of SNVs (non-coding, synonymous, missense, and loss-of-

541 function (nonsense or essential splice)) and indels (non-coding indel and coding indel) per sperm cell. The red

542 points represent the observed values for each individual. The grey line represents the expected mutation count

543 per sperm based on the germline mutation rate model. Error bands indicate 95% CIs of linear regressions.



544

545 Extended Data Fig. 7 | Phenotype correlations

546 Correlation of cohort phenotypes to mutation outcome variables, with different sequencing datasets

- split by facets. Joint predictor glm models used the gaussian family with FDR corrected *P* values.
- 548 Asterisks indicate significance level of corrected *P* value: (**P* value >0.01 to <0.05, ***P* value >0.001

549 to <0.01, ****P* value <0.001).

chr	pos	ref	mut	gene	aachange	impact	obs	exp	dnds_ratio	qval_exome	qval_RHT
4	1806119	G	А	FGFR3	G382R	Missense	10	0.007750	1290	2.69e-06	2.33e-11
10	123274774	А	G	FGFR2	C383R	Missense	5	0.000803	6226	3.33e-05	2.88e-10
4	1807889	А	G	FGFR3	K652E	Missense	4	0.000225	17816	3.33e-05	2.88e-10
12	112926909	А	G	PTPN11	Q510R	Missense	5	0.000925	5406	4.46e-05	NA
12	112888168	Т	G	PTPN11	Y62D	Missense	4	0.000303	13198	6.62e-05	NA
18	48604664	С	т	SMAD4	R496C	Missense	9	0.011300	793	1.81e-04	2.20e-09
12	112888172	А	G	PTPN11	Y63C	Missense	6	0.003010	1994	1.81e-04	2.20e-09
18	48604676	А	G	SMAD4	1500V	Missense	5	0.002230	2244	1.73e-03	2.00e-08
17	27086078	С	т	FAM222B	R300H	Missense	5	0.002320	2157	1.87e-03	NA
22	41572254	Т	G	EP300	F1595V	Missense	3	0.000176	17044	2.90e-03	3.58e-08
12	112926890	А	G	PTPN11	M504V	Missense	4	0.000963	4154	2.90e-03	3.58e-08
12	112926887	G	А	PTPN11	G503R	Missense	4	0.000975	4101	2.90e-03	NA
1	155874263	Т	С	RIT1	M107V	Missense	5	0.003180	1572	6.09e-03	NA
4	1803571	С	G	FGFR3	P250R	Missense	3	0.000337	8912	1.64e-02	NA
1	155874285	А	С	RIT1	F99L	Missense	3	0.000349	8600	1.70e-02	NA
10	123279677	G	С	FGFR2	S252W	Missense	3	0.000491	6106	4.45e-02	6.85e-07
18	19426998	С	т	MIB1	R769*	Nonsense	4	0.002190	1825	5.05e-02	NA
12	112926270	С	т	PTPN11	T468M	Missense	4	0.003070	1301	1.80e-01	2.81e-06
12	112888199	С	т	PTPN11	A72V	Missense	3	0.000861	3484	2.00e-01	3.00e-06
12	112926851	С	т	PTPN11	P491S	Missense	3	0.000936	3205	2.44e-01	3.50e-06
11	533874	Т	С	HRAS	Q61R	Missense	3	0.000959	3127	2.50e-01	3.50e-06
3	12645699	G	А	RAF1	S257L	Missense	4	0.012700	314	1.00e+00	4.61e-04
4	1803564	С	т	FGFR3	R248C	Missense	3	0.005820	516	1.00e+00	6.16e-04
11	534289	С	т	HRAS	G12S	Missense	3	0.010100	297	1.00e+00	2.79e-03
17	29654736	С	т	NF1	R1830C	Missense	3	0.013200	228	1.00e+00	5.53e-03

Extended Data Table 1 | Significant SNV hotspots from dN/dS exome-wide and

restricted hypothesis tests (RHT)

557 Methods

558 Ethics

This study was carried out under TwinsUK BioBank ethics, approved by North West – Liverpool
Central Research Ethics Committee (REC reference 19/NW/0187), IRAS ID 258513 and earlier

- approvals granted to TwinsUK by the St Thomas' Hospital Research Ethics Committee, later London
- 562 Westminster Research Ethics Committee (REC reference EC04/015).
- 563

564 Sample collection

Bulk semen samples were collected or obtained from archival samples with informed consent from 75 565 research participants within the TwinsUK cohort²⁶. Archival whole-blood samples were also obtained 566 from 67 of those men from the TwinsUK BioBank. A total of 104 semen samples spanned an age range 567 568 of 24-75 years and included 29 men with 2 timepoints separated by a mean of 12.1 years (range 12-13 vears) and the remaining 46 men with a single timepoint. A total of 133 blood samples were collected 569 570 at an age range of 22-83 years. There were 11 men with a single blood timepoint, 47 with two 571 timepoints, 8 with three timepoints and 1 with four timepoints. The mean interval between blood timepoints was 8.1 years (range 1-13 years). Within the cohort there were a total of 9 monozygotic 572 573 (MZ) twins and 3 dizygotic (DZ) twin pairs. Counts of samples, timepoints, and twin pairs which were 574 successfully sequenced and passed analysis quality control thresholds are summarised in 575 Supplementary Table 1.

576

577 Metadata

578 Metadata for self-reported age, height, weight, ethnicity, twin zygosity, smoking and alcohol 579 consumption were obtained from questionnaires provided by TwinsUK taken periodically. All 580 individuals that provided ethnicity information indicated "white". BMI was calculated as 581 weight/height². A smoking pack year was defined as 365 packs of cigarettes and total pack years was 582 calculated using the highest estimate across all questionnaires from cigarettes per day or week and total 583 years smoked. Alcohol drink years was calculated from using average weekly alcohol consumption 584 extrapolated to the duration of adult life before sampling (age - 18).

585

586 **DNA extraction**

587 DNA was extracted from sperm samples using the Qiagen QIAamp DNA Blood Mini Kit. Isolation of

588 genomic DNA from sperm; protocol 1 (QA03 Jul-10) was followed with the exceptions of substituting

589 DTT in place of β -mercaptoethanol for Buffer 2 and substituting Buffer EB in place of Buffer AE for

elution of DNA.

- 591 DNA was extracted from whole blood using the Gentra Puregene Blood Kit, following the protocol for
- 592 10ml of compromised whole blood from the Gentra Puregene Handbook version 06/2011.
- 593

Targeted gene panels 594

595 Three separate Twist Bioscience gene panels were used for targeted NanoSeq sequencing in this study: 596 1) a custom pilot panel of 210 genes; 2) a similar but extended custom panel of 263 genes 597 (Supplementary Table 2); 3) a default exome-wide panel of 18,800 genes. The two custom gene panels 598 are highly similar with the extended panel being almost exclusively regions added to the pilot panel. 599 From the 84 samples that underwent targeted sequencing, 13 were sequenced using a pilot panel of 210 canonical cancer/somatic driver genes, and all 84 were sequenced using the extended panel of 263 600 601 genes. Sequencing coverage and mutations were merged from samples sequenced on both targeted 602 panels. The custom panels were designed by gathering sets of published lists of genes implicated as drivers in cancers⁷¹⁻⁷⁴ and somatic tissues^{1,75} as described in (Lawson A.R., Abascal F., P.A. Nicola et 603 al., manuscript submitted for publication). 604

605

Sequencing and preprocessing of NanoSeq libraries 606

607 Restriction-enzyme whole genome NanoSeq libraries were prepared as described in Abascal et al.²³ and subjected to whole genome sequencing at target 20-30x coverage on NovaSeq (Illumina) platforms to 608 609 generate 150-bp paired-end reads with 9-10 samples per lane. Standard whole genome sequencing of 610 blood (31.7x median coverage) was used to generate matched-normal libraries for both restriction-611 enzyme NanoSeq blood and sperm.

612

613 Targeted and exome NanoSeq libraries were prepared via sonication and 1-2 rounds of pull down of target sequences as described in (Lawson A.R., Abascal F., P.A. Nicola et al., manuscript submitted for 614 publication). They were then sequenced with NovaSeq (Illumina) platforms to generate 150-bp paired-615

- end reads with 7-8 samples per lane for the targeted panel and 2 lanes per sample for the exome panel. 616
- 617

Base calling and filtering 618

All samples were processed using a Nextflow implementation of the NanoSeq calling pipeline 619 (https://github.com/cancerit/NanoSeq). BWA-MEM⁷⁶ was used to align all sequences to the human 620 621 reference genome (NCBI build37). Restriction-enzyme NanoSeq samples were called with their matched WGS normal and default parameters except for var b (minimum matched normal reads per 622 623 strand) of 5 as needed for WGS normals, cov Q (minimum mapQ to include a duplex read) of 15 and 624 var n (maximum number of mismatches) of 2.

626 For targeted and exome samples we leveraged the high sequencing depth and high polyclonality to 627 exclude variants with VAF > 10% instead of using a matched normal. Default parameters of the calling 628 pipeline except for cov Q of 30, var n of 2, var z (minimum normal coverage) of 25, var a (minimum 629 AS-XS) of 10, var v (maximum normal variant allele frequency (VAF)) of 0.1, and indel v (maximum normal VAF) of 0.1. Post variant calling, we further filtered variants to those below 1% VAF and those 630 631 below 10% duplex VAF as variants above these cutoffs were highly enriched for mapping artefacts. particularly for indels. No excluded variants from these additional VAF thresholds were found to be 632 likely driver or ClinVar pathogenic variants; all exclusions were inspected to confirm this. 633

634

A set of common germline variants from dbsnp⁷⁷ and a custom set of known artifactual call sites in 635

NanoSeq datasets were masked for coverage and variant calls as previously described²³. 636

637

Assessing DNA contamination 638

The single-molecule accuracy of the duplex sequencing method NanoSeq allows sequencing of 639 640 polyclonal cell types such as sperm, but also renders mutation calls sensitive to a) non-target cell-type 641 contamination and b) contamination of foreign DNA. Non-target cell-type contamination was evaluated using manual cell counting of semen samples, resulting in the exclusion of 6 samples with sperm count 642 643 < 1 million sperm/mL. Sperm counting methods and analysis are detailed in Supplementary Note 1.

644

645 Foreign DNA contamination in whole genome NanoSeq samples was assessed using verifyBamID⁷⁸, which checks whether reads in a BAM file match previous genotypes for a specific sample, with higher 646 647 values indicating more contamination. Three blood whole genome NanoSeq samples were excluded based on a verifyBamID alpha value above the suggested cutoff of 0.005^{23} . In sperm, we found that 648 649 several samples had outlier mutation burdens with verifyBamID values just below the 0.005 cutoff. 650 This is logical, as sperm has a much lower mutation rate compared to somatic tissues, for which the recommended cutoff was designed. Consequently, sperm samples are more sensitive to low levels of 651 652 contamination. To account for this, we adjusted the verifyBamID alpha threshold for sperm to a more 653 stringent level of 0.002, resulting in the exclusion of 3 samples on this criterion.

654

When assessing foreign DNA contamination in targeted and exome samples we found that 9 targeted 655 656 and 3 exome samples had verify BamID values above > 0.002, slight outlier mutation burdens, and high 657 ratio of SNP masked variants to passed variants (4-fold to 16-fold more masked variants). Upon further 658 investigation we found that all samples exceeding verifyBamID thresholds were processed in the same 659 sequencing batch and that this contamination could be explained by inherited germline variants of other 660 samples within that same batch. This suggests that a small amount of cross-contamination may have occurred during sample preparation or sequencing steps. In order to remove contaminant germline 661

mutations we performed an *in silico* decontamination as previously described²³. This involved calling 662 germline variants from all targeted and exome samples using beftools mpileup⁷⁹ at sites where there 663 were >10 reads and a mutation call with VAF > 0.3. All such sites were subsequently masked across all 664 samples for both mutation calls and coverage, essentially extending the default common SNP mask to 665 also include rare inherited variants across the cohort. This resulted in all samples previously identified 666 as contaminated having mutation burdens consistent with their age and all having a ratio of masked to 667 668 passed variants <0.1, and were thus retained for analysis.

669

Corrected mutation burdens 670

Given that mutation rates are strongly influenced by trinucleotide composition, it is important to 671 672 consider differences in sequence composition when comparing mutation rates in datasets that target different regions of the genome. For instance, it is known that coding regions such as those in NanoSeq 673 target panels, are biased towards a higher mutation rate partially due to a higher GC density than non-674 coding regions⁸⁰ which make up the majority of sequenced regions in whole genome NanoSeq datasets. 675 676 To correct for this effect, in each sperm NanoSeq dataset we generated a corrected mutation burden relative to the full genome trinucleotide frequencies as described previously²³. 677

678

Comparison of NanoSeq and WGS burden estimates 679

680 In order to compare whole genome NanoSeq mutation burdens to mutation burden from standard whole 681 genome sequencing (WGS) we multiplied the corrected mutation burden estimates described in the 682 previous section by the genome size per cell type. We assumed 2,861,326,455 mappable base pairs in a haploid cell for germline datasets and the diploid equivalent of 5,722,652,910 base pairs for blood. 683

684

External datasets for comparison to NanoSeq results were processed in order to achieve comparable 685 burden estimates. For testis WGS samples⁷⁰ we implemented the method described in Abascal et al.²³ 686 687 that restricts analysis to regions with high coverage (20+ reads) that overlap with NanoSeq covered regions. Additionally, we corrected for differences in trinucleotide background frequencies relative to 688 689 the full genome as described in the previous section. For trio paternally phased DNMs from standard 690 sequencing, as a callable genome size per sample following thorough filtering was available, we 691 generated the mutation per cell estimate by multiplying the paternally phased DNM count by the ratio 692 of the sample's callable genome to total genome size. For comparison to cell types in blood we 693 compared directly to the published mutation burden regressions⁸.

694

695 **Mutation burden regressions**

696 To investigate the relationship between age and mutation burdens, we performed linear mixed-effects 697 regression analyses. For each tissue and mutation type where a regression was performed, the model

was constructed using the `lmer` function from the `lme4` package⁸¹ in R. Each model included age at
sampling as a fixed effect and a random slope for each individual to account for multiple timepoint
samples, specified as:

- 701
- 702

lmer(burden ~ age + (age - 1| indiv_ID), REML=F)

703

The 95% confidence intervals (CIs) for regression lines were calculated through bootstrapping by simulating prediction intervals. For each model, we generated 1000 bootstrap samples. Predictions and their associated standard errors were calculated for a sequence of ages from 14 to 84 years. The 95% CIs were then derived by determining the range within which 95% of the bootstrap sample predictions fell.

709

710 Mutational signature analysis

711 We extracted *de novo* mutational signatures using Hierarchical Dirichlet Process (HDP; 712 https://github.com/nicolaroberts/hdp), which is based on the Bayesian Hierarchical Dirichlet process. 713 HDP was run with double hierarchy: (1) individual ID and (2) tissue types (either blood or sperm), and without the Catalogue Of Somatic Mutations In Cancer (COSMIC) reference signatures⁸² (v3.3) as 714 priors, on the mutation matrices. The number of mutations were normalised for the tri-nucleotide 715 716 context abundance specific for each sample relative to the full genome. Both clustering hyper-717 parameters, beta and alpha, were set to one. The Gibbs samples ran for 30,000 burn-in iterations 718 (parameter "burnin"), with a spacing of 200 iterations (parameter "space"), from which 100 iterations 719 were collected (parameter "n"). After each Gibbs iteration, three iterations of concentration parameters 720 were conducted (parameter "cpiter"). Two components were extracted as *de novo* mutational signatures 721 which were further reconstructed and decomposed into known COSMICv3.3 SBS signatures using 722 SigProfilerAssignment (https://github.com/AlexandrovLab/SigProfilerAssignment). As a result, three 723 COSMIC signatures: SBS1, SBS5, and SBS19, were reported.

724 Quantifying selection with dN/dS

To examine genes under positive selection and quantify global selection we used the *dNdScv* algorithm²⁹. This algorithm was extended using base pair level duplex coverage, methylation level and pentanucleotide context to capture more complex context dependent mutational biases, and to achieve more accuracy for our selection analysis. Detailed methods for input mutations, model selection and evaluation, site dN/dS tests, driver mutation estimation, and gene set enrichment are described in **Supplementary Note 3**.

Gene disease and mechanism annotation 731

Positively selected genes were annotated with monoallelic disease consequences using the 2024-02-29 732 release of the Development Disorder Genotype - Phenotype Database (DDG2P)³³ and the 2024-06-21 733 release of the Online Mendelian Inheritance in Man (OMIM) database⁴⁵. OMIM annotations related to 734 735 somatic disease, complex disease, or tentative disease associations were excluded.

736

737 Genes were also annotated for their potential mutation mechanism observed in sperm and cancer/developmental disorders when available. In sperm, genes were labelled as loss-of-function if 738 739 they had nominal enrichment of nonsense+splice variants and/or indel variants (ptrunc cv < 0.1740 pind cv < 0.1) and 2+ loss-of-function mutations. There were two exceptions to this where genes met 741 these thresholds but were labelled as activating due to having a restricted repertoire of loss of function 742 mutations that are known to be oncogenic in cancers: CBL (LOFs in and downstream of the RING zinc finger domain)⁸³ and *PPM1D* (LOFs in final two exons)⁸⁴. All other genes had missense enrichment 743 only and were labelled as activating. The mechanism in cancer was defined by using the 'Role in Cancer' 744 field of the COSMIC cancer gene census v99³² where 'oncogene' was labelled as activating and 'tumour 745 suppressor gene' as loss of function. Annotations of a fusion mechanism were not displayed except for 746 747 genes which had neither an oncogene, nor a tumour suppressor annotation which were labelled as 748 'fusion only'. The developmental disorder mechanism was defined by using the variation consequence 749 field of DDG2P where 'restricted repertoire of mutations; activating' was labelled as activating and 750 'loss of function variant' was labelled as loss of function.

Gene mutation plots 751

The "lollipop" gene mutation plots were created with a coordinate system where the 1 was the first 752 coding base of the GRCh37-GencodeV18+Appris⁸⁵ transcript of the gene. The data sources included 753 protein domains from UniProt⁸⁶, somatic mutations from the exome and genome wide screens of the 754 COSMIC³² (v99), ClinVar release 2024.07.01³⁴ pathogenic annotation, per base pair cohort wide 755 756 (targeted + exome) NanoSeq coverage, sperm mutation count (number of independent individuals with a mutation) and mutation consequence and amino acid change annotated by the dNdScv algorithm²⁹. 757 These data were plotted with code modified from the lolliplot function in the trackViewer R package⁸⁷. 758

Variant annotation 759

760 Variants were annotated using Ensembl's Variant Effect Predictor (VEP)⁸⁸ with added custom annotations of mutation context, ClinVar release 2024.07.01³⁴, Combined Annotation Dependent 761 Depletion (CADD) version GRCh37-v1.6⁵³ and average methylation level in testis. Methylation data 762 was obtained from whole genome shotgun bisulfite sequencing methylation data from a 37 year old 763 (ENCFF638QVP) and 54 year old (ENCFF715DMX) male testis from the ENCODE project⁷⁰. The 764

average methylation level was calculated by selecting CpG sites with coverage of 3 or more and averaging the percent of sites methylated between the two samples.

767

768 Variants were annotated as likely monoallelic disease-causing mutations if they met at least one of two 769 criteria: 1) Reported in ClinVar as pathogenic, likely pathogenic, or if they were reported as 770 'Conflicting classifications of pathogenicity' where the conflict was between reports of 771 pathogenic/likely pathogenic and 'Uncertain significance' with no reports of benign or likely benign 772 and not specified as a recessive condition or 2) Were a highly damaging variant in a high confidence monoallelic developmental disorder genes from DDG2P³³. Genes met criteria of a) allelic requirement 773 being monoallelic autosomal, monoallelic X hem, monoallelic X het, or mitochondrial, b) 774 775 confidence in strong, definitive, or moderate and c) a mutation consequence of 'absent gene product'. 776 Highly damaging was defined as being a 'HIGH' impact variant in VEP annotation (frameshift 777 splice acceptor, splice donor, start lost, stop gained, or stop lost) or a missense variant with CADD⁵³ 778 score >30 (top 0.1% damaging).

779

780 Variants were defined as a likely driver if they met the 'highly damaging' criteria defined above in a 781 significant germline selection gene with loss-of-function mutation enrichment or if they were in one of 782 the 24 significant mutation hotspots. This resulted in 320 variants being labelled as likely drivers in 783 exome samples.

784 Cell fraction mutation estimates

785 To calculate the mean count of synonymous, missense or loss-of-function, or pathogenic mutations per sperm cell we summed the duplex VAFs of all variants in that class. For example, if an individual had 786 787 three synonymous mutations each observed once with a duplex coverage of 100 at each of those sites, 788 each of those variants would have a duplex VAF of 1/100 = 0.01. The sum of VAFs in this example 789 would then be 0.03 and this would then be reported as the estimate for the mean count of synonymous 790 variants per sperm cell for that individual. At low fractions such as 0.03, the mean count per cell is 791 approximately equivalent to the percentage of sperm with this mutation class (3%) and thus the driver 792 and disease mutations are reported as percentage estimates. At higher fractions (e.g. mean count > 1) 793 the fractions are not equivalent to percentage as many cells will have multiple variants of that class and 794 thus the estimates are reported as mean count.

795

Expected mean counts for SNVs were generated by annotating each possible substitution at each covered site with an expected number of mutations per sample as given by expCountSNV = context_mut_rate*duplex_coverage*age_correction. The context_mut_rate was given by the 208 basePairCov + cpgMeth trinucleotide mutation model estimates for that trinucleotide+methylation

800 mutation context (Supplementary Note 3; Supplementary Table 6). Duplex coverage is the exact 801 duplex coverage at that site for that sample. The age correction parameter was given to normalise the 802 mutation model estimates (derived from all exome samples) to the mutation rate of that sample based 803 on age. Specifically, we fit a linear model to the mutation burden vs age of the exome samples and used 804 this to generate a predicted mutation rate for each sample based on age. The per sample corrected 805 parameter was calculated as the age predicted mutation burden divided by the mean mutation rate of all 806 exome samples (3.89e-08). The resulting corrections spanned from 0.50 (youngest sample) to 1.42 807 (oldest samples). The expected indel mutation rate was calculated in the same way, except with a single expCountIndel 808 mutation rate parameter (indels/bp) = indel mut rate*duplex coverage*age correction. The expected mean count was then calculated for 809 810 each category (e.g. synonymous, likely disease) by summing the expected values for each SNV and/or 811 indel base pair matching the relevant annotation. As background for possible ClinVar pathogenic 812 variants we only considered indels of size 21 bp or less, the largest detected indel in the dataset. 813 Regressions were fit with either linear models or generalised linear models (glm in R) with family = 814 quasibinomial.

815 **Regression analysis**

We tested for associations between mutation outcome variables from sperm genome, sperm exome, 816 817 sperm targeted and blood genome NanoSeq data and the phenotype predictor variables of BMI, smoking 818 pack years, and alcohol drink years. These tests were performed using a gaussian family generalised 819 linear regression in R. For each mutation outcome variable the test took the form of: glm(mutationOutcome ~ age at sampling + BMI + pack years + drinkYears, family = "gaussian"). 820

821

822 The mutation outcome variables examined were SNV and indel burden from all 4 sequencing datasets, 823 SBS1 and SBS5 count from sperm genomes, SBS1, SBS5, and SBS19 from blood genomes, and likely 824 disease cell fraction and likely driver cell fraction from sperm targeted and sperm exomes. The 825 significance of each predictor was assessed from the model's summary output coefficients, and p-values 826 were adjusted for 68 total tests using the false discovery rate method.

- 827
- 828
- 829 830
- 831

832

833

Data availability 834

835 Raw sequencing data are available on the European Genome–Phenome Archive under accession 836 number X. Additional individual-level data are not permitted to be publicly shared or deposited due to the original consent given at the time of data collection, where access to these data is subject to 837 governance oversight. All data access requests are overseen by the TwinsUK Resource Executive 838 839 Committee (TREC). For information on access to these genotype and phenotype data and how to apply. 840 see https://twinsuk.ac.uk/resources-for-researchers/access-our-data/.

841

Code availability 842

All scripts are available on github at https://github.com/mattnev17/spermPositiveSelectionManuscript. 843 844

845 Acknowledgements

846 We thank the TwinsUK research volunteers for participating in the study. We are grateful to Laura 847 O'Neill, Calli Latimer and all of the CASM Support team at the Wellcome Sanger Institute for their 848 assistance. We thank Charlotte Seymour, Elisa Ferraro, and Chris White from Cambridge IVF for 849 training and guidance on sperm counting.

850

Funding 851

852 This research is supported by core funding from Wellcome Trust. R.R. is funded by Cancer Research UK (C66259/A27114) and Medical Research Council (MR/W025353/1). TwinsUK is funded by the 853 854 Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic 855 Disease Research Foundation (CDRF), Zoe Ltd, the National Institute for Health and Care Research 856 (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guy's and St 857 Thomas' NHS Foundation Trust in partnership with King's College London. 858

859 **Author Contributions**

M.D.C.N., M.E.H. and R.R. wrote the manuscript; all authors reviewed and edited the manuscript. 860 M.E.H., and R.R. supervised the project. M.P.G., S.W., K.S., and R.R. led sample procurement.

M.D.C.N., T.B., and P.A.N. conducted sperm counting. A.R.J.L., P.J.C., K.R., S.V.L., S.W., and I.M. 862

- contributed to sample sequencing implementation. M.D.C.N., led the analysis of the data with help from 863
- 864 A.R.J.L., R.S., F.A., M.H.P., A.C., P.A.N., A.B.O., R.E.A., M.R.S., P.J.C., I.M., M.E.H., and R.R.
- 865

866 **Competing Interests**

- 867 I.M., M.R.S., and P.J.C. are co-founders, shareholders, and consultants for Quotient Therapeutics Ltd.
- 868 R.E.A. is an employee of Quotient Therapeutics Ltd. M.E.H. is a co-founder of, consultant to and holds
- shares in Congenica, a genetics diagnostic company.
- 870
- 871
- 872
- 873

874 **References**

- 1. Martincorena, I. et al. High burden and pervasive positive selection of somatic mutations in normal
- 876 human skin. *Science* **348**, 880–886 (2015).
- 2. Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362,
- 878 911–917 (2018).
- 879 3. Brunner, S. F. *et al.* Somatic mutations and clonal dynamics in healthy and cirrhotic human liver.
- 880 *Nature* **574**, 538–542 (2019).
- 4. Lee-Six, H. *et al.* The landscape of somatic mutation in normal colorectal epithelial cells. *Nature*574, 532–537 (2019).
- 5. Moore, L. *et al.* The mutational landscape of normal human endometrial epithelium. *Nature* 580,
 640–646 (2020).
- 6. Lawson, A. R. J. *et al.* Extensive heterogeneity in somatic mutation and selection in the human
 bladder. *Science* 370, 75–82 (2020).
- 7. Moore, L. *et al.* The mutational landscape of human somatic and germline cells. *Nature* 597, 381–
 386 (2021).
- 889 8. Machado, H. E. *et al.* Diverse mutational landscapes in human lymphocytes. *Nature* 608, 724–732
 890 (2022).
- 891 9. Mitchell, E. *et al.* Clonal dynamics of haematopoiesis across the human lifespan. *Nature* 606, 343–
 892 350 (2022).
- Bernstein, N. *et al.* Analysis of somatic mutations in whole blood from 200,618 individuals
 identifies pervasive positive selection and novel drivers of clonal hematopoiesis. *Nat. Genet.* 1–9
 (2024) doi:10.1038/s41588-024-01755-1.
- Heller, C. H. & Clermont, Y. Kinetics of the germinal epithelium in man. *Recent Prog. Horm. Res.* 20, 545–575 (1964).
- Neto, F. T. L., Bach, P. V., Najari, B. B., Li, P. S. & Goldstein, M. Spermatogenesis in
 humans and its affecting factors. *Semin. Cell Dev. Biol.* 59, 10–26 (2016).
- 900 13. Goriely, A., McVean, G. A. T., Röjmyr, M., Ingemarsson, B. & Wilkie, A. O. M. Evidence
- 901 for Selective Advantage of Pathogenic FGFR2 Mutations in the Male Germ Line. *Science* **301**,

- 902 643–646 (2003).
- 903 14. Choi, S.-K., Yoon, S.-R., Calabrese, P. & Arnheim, N. Positive Selection for New Disease
- 904 Mutations in the Human Germline: Evidence from the Heritable Cancer Syndrome Multiple
- 905 Endocrine Neoplasia Type 2B. *PLOS Genet.* **8**, e1002420 (2012).
- 906 15. Maher, G. J., Goriely, A. & Wilkie, A. O. M. Cellular evidence for selfish spermatogonial
- selection in aged human testes. *Andrology* **2**, 304–314 (2014).
- 908 16. Maher, G. J. et al. Visualizing the origins of selfish de novo mutations in individual
- 909 seminiferous tubules of human testes. *Proc. Natl. Acad. Sci.* **113**, 2454–2459 (2016).
- 910 17. Eboreime, J. et al. Germline selection of PTPN11 (HGNC:9644) variants make a major
- 911 contribution to both Noonan syndrome's high birth rate and the transmission of sporadic cancer
- 912 variants resulting in fetal abnormality. *Hum. Mutat.* **43**, 2205–2221 (2022).
- 913 18. Wood, K. A. & Goriely, A. The impact of paternal age on new mutations and disease in the
- next generation. *Fertil. Steril.* (2022) doi:10.1016/j.fertnstert.2022.10.017.
- 915 19. Goriely, A. & Wilkie, A. O. M. Paternal age effect mutations and selfish spermatogonial
- 916 selection: causes and consequences for human disease. *Am. J. Hum. Genet.* **90**, 175–200 (2012).
- 917 20. Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat.
- 918 *Protoc.* **9**, 2586–2606 (2014).
- Schmitt, M. W. *et al.* Detection of ultra-rare mutations by next-generation sequencing. *Proc. Natl. Acad. Sci.* 109, 14508–14513 (2012).
- 921 22. Hoang, M. L. *et al.* Genome-wide quantification of rare somatic mutations in normal human
 922 tissues using massively parallel sequencing. *Proc. Natl. Acad. Sci.* 113, 9846–9851 (2016).
- Abascal, F. *et al.* Somatic mutation landscapes at single-molecule resolution. *Nature* 593,
 405–410 (2021).
- 925 24. Liu, M. H. *et al.* DNA mismatch and damage patterns revealed by single-molecule
- 926 sequencing. *Nature* 1–10 (2024) doi:10.1038/s41586-024-07532-8.
- 927 25. Kunisaki, J. *et al.* Sperm from infertile, oligozoospermic men have elevated mutation rates.
- 928 Preprint at https://doi.org/10.1101/2024.08.22.24312232 (2024).
- 929 26. Verdi, S. et al. TwinsUK: The UK Adult Twin Registry Update. Twin Res. Hum. Genet. 22,

- 930 523–529 (2019).
- 931 27. Sasani, T. A. *et al.* Large, three-generation human families reveal post-zygotic mosaicism and
 932 variability in germline mutation accumulation. *eLife* 8, e46922 (2019).
- 933 28. Campbell, P. et al. Prolonged persistence of mutagenic DNA lesions in stem cells. Preprint at
- 934 https://doi.org/10.21203/rs.3.rs-3610927/v1 (2023).
- 935 29. Martincorena, I. et al. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell
- 936 **171**, 1029-1041.e21 (2017).
- 937 30. Carlson, J. et al. Extremely rare variants reveal patterns of germline mutation rate
- heterogeneity in humans. *Nat. Commun.* **9**, 3753 (2018).
- 31. Xia, B. *et al.* Widespread Transcriptional Scanning in the Testis Modulates Gene Evolution
 Rates. *Cell* 180, 248-262.e21 (2020).
- 32. Sondka, Z. *et al.* The COSMIC Cancer Gene Census: describing genetic dysfunction across
 all human cancers. *Nat. Rev. Cancer* 18, 696–705 (2018).
- 33. Thormann, A. *et al.* Flexible and scalable diagnostic filtering of genomic variants using G2P
 with Ensembl VEP. *Nat. Commun.* 10, 2373 (2019).
- 34. Landrum, M. J. *et al.* ClinVar: improving access to variant interpretations and supporting
 evidence. *Nucleic Acids Res.* 46, D1062–D1067 (2018).
- 947 35. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new
- 948 perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 45, D353–D361
 949 (2017).
- 950 36. Digre, A. & Lindskog, C. The Human Protein Atlas—Spatial localization of the human
 951 proteome in health and disease. *Protein Sci. Publ. Protein Soc.* 30, 218–233 (2021).
- 37. Imielinski, M., Guo, G. & Meyerson, M. Insertions and Deletions Target Lineage-Defining
 Genes in Human Cancers. *Cell* 168, 460-472.e14 (2017).
- 8. Rheinbay, E. *et al.* Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature* 578, 102–111 (2020).
- 39. Kaplanis, J. *et al.* Evidence for 28 genetic disorders discovered by combining healthcare and
 research data. *Nature* 586, 757–762 (2020).

- 958 40. Wood, K. A. *et al. SMAD4* mutations causing Myhre syndrome are under positive selection in
- 959 the male germline. Am. J. Hum. Genet. (2024) doi:10.1016/j.ajhg.2024.07.006.
- 960 41. Waite, K. A. & Eng, C. From developmental disorder to heritable cancer: it's all in the
- 961 BMP/TGF-β family. *Nat. Rev. Genet.* **4**, 763–773 (2003).
- 962 42. Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and
- 963 cancer. Nat. Rev. Cancer 7, 295–308 (2007).
- 964 43. Qi, H., Dong, C., Chung, W. K., Wang, K. & Shen, Y. Deep Genetic Connection Between
 965 Cancer and Developmental Disorders. *Hum. Mutat.* 37, 1042–1050 (2016).
- 966 44. Yavuz, B. R. et al. Neurodevelopmental disorders and cancer networks share pathways, but
- 967 differ in mechanisms, signaling strength, and outcome. *Npj Genomic Med.* **8**, 1–14 (2023).
- 45. Amberger, J. S., Bocchini, C. A., Scott, A. F. & Hamosh, A. OMIM.org: leveraging
- knowledge across phenotype-gene relationships. *Nucleic Acids Res.* 47, D1038–D1043 (2019).
- 970 46. Deng, Z. et al. Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by
- 971 Mutations in the Bone Morphogenetic Protein Receptor–II Gene. *Am. J. Hum. Genet.* 67, 737–744
 972 (2000).
- 47. Momose, Y. *et al.* De novo mutations in the BMPR2 gene in patients with heritable

pulmonary arterial hypertension. Ann. Hum. Genet. 79, 85–91 (2015).

- 48. Evans, J. D. W. *et al.* BMPR2 mutations and survival in pulmonary arterial hypertension: an
 individual participant data meta-analysis. *Lancet Respir. Med.* 4, 129–137 (2016).
- 49. Bashamboo, A., Bignon-Topalovic, J., Moussi, N., McElreavey, K. & Brauner, R. Mutations
 in the Human ROBO1 Gene in Pituitary Stalk Interruption Syndrome. *J. Clin. Endocrinol. Metab.*102, 2401–2406 (2017).
- 980 50. Liu, Z. & Chen, X. A Novel Missense Mutation in Human Receptor Roundabout-1 (ROBO1)
- Gene Associated with Pituitary Stalk Interruption Syndrome. J. Clin. Res. Pediatr. Endocrinol. 12,
 212–217 (2020).
- 51. Liu, C. *et al.* Deficiency of primate-specific SSX1 induced asthenoteratozoospermia in
 infertile men and cynomolgus monkey and tree shrew models. *Am. J. Hum. Genet.* 110, 516–530
 (2023).

- 986 52. Alankarage, D. et al. Myhre syndrome is caused by dominant-negative dysregulation of
- 987 SMAD4 and other co-factors. *Differentiation* **128**, 1–12 (2022).
- 988 53. Rentzsch, P., Schubach, M., Shendure, J. & Kircher, M. CADD-Splice-improving genome-
- 989 wide variant effect prediction using deep learning-derived splice scores. *Genome Med.* 13, 31
- 990 (2021).
- 991 54. Luyckx, I., Verstraeten, A., Goumans, M.-J. & Loeys, B. SMAD6-deficiency in human
- genetic disorders. *Npj Genomic Med.* 7, 1–11 (2022).
- 993 55. Sherwood, K. et al. Germline de novo mutations in families with Mendelian cancer
- 994 syndromes caused by defects in DNA repair. *Nat. Commun.* 14, 3636 (2023).
- 995 56. Garcia-Salinas, O. I. et al. The impact of ancestral, environmental and genetic influences on
- germline de novo mutation rates and spectra. 2024.05.17.594464 Preprint at
- 997 https://doi.org/10.1101/2024.05.17.594464 (2024).
- 998 57. Balmain, A. The critical roles of somatic mutations and environmental tumor-promoting
 999 agents in cancer risk. *Nat. Genet.* 52, 1139–1143 (2020).
- 1000 58. Turner, T. N. *et al.* denovo-db: a compendium of human de novo variants. *Nucleic Acids Res.*1001 45, D804–D811 (2017).
- 1002 59. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
- 1003 141,456 humans. *Nature* **581**, 434–443 (2020).
- 1004 60. Kong, A. *et al.* Rate of de novo mutations, father's age, and disease risk. *Nature* 488, 471–
 1005 475 (2012).
- 1006 61. Rahbari, R. *et al.* Timing, rates and spectra of human germline mutation. *Nat. Genet.* 48, 126–
 1007 133 (2016).
- 1008 62. Jónsson, H. *et al.* Parental influence on human germline de novo mutations in 1,548 trios
 1009 from Iceland. *Nature* 549, 519–522 (2017).
- 1010 63. Kaplanis, J. *et al.* Genetic and chemotherapeutic influences on germline hypermutation.
- 1011 *Nature* **605**, 503–508 (2022).
- 1012 64. Kingdom, R. et al. Rare genetic variants in genes and loci linked to dominant monogenic
- 1013 developmental disorders cause milder related phenotypes in the general population. *Am. J. Hum.*

- 1014 Genet. 109, 1308–1316 (2022).
- 1015 65. Giannoulatou, E. et al. Whole-genome sequencing of spermatocytic tumors provides insights
- 1016 into the mutational processes operating in the male germline. *PLOS ONE* **12**, e0178169 (2017).
- 1017 66. Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of
- 1018 carcinogenesis. Br. J. Cancer 8, 1–12 (1954).
- 1019 67. Nowell, P. C. The clonal evolution of tumor cell populations. *Science* **194**, 23–28 (1976).
- 1020 68. Cimadomo, D. et al. Impact of Maternal Age on Oocyte and Embryo Competence. Front.
- 1021 Endocrinol. 9, 327 (2018).
- 1022 69. Paul, C. & Robaire, B. Ageing of the male germ line. *Nat. Rev. Urol.* 10, 227–234 (2013).
- 1023 70. Moore, J. E. et al. Expanded encyclopaedias of DNA elements in the human and mouse
- 1024 genomes. *Nature* **583**, 699–710 (2020).
- 1025 71. Gao, Y.-B. *et al.* Genetic landscape of esophageal squamous cell carcinoma. *Nat. Genet.* 46,
 1026 1097–1102 (2014).
- 1027 72. Waddell, N. *et al.* Whole genomes redefine the mutational landscape of pancreatic cancer.
 1028 *Nature* **518**, 495–501 (2015).
- 1029 73. Aaltonen, L. A. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
- 1030 74. Nguyen, B. *et al.* Genomic characterization of metastatic patterns from prospective clinical
- 1031 sequencing of 25,000 patients. *Cell* **185**, 563-575.e11 (2022).
- 1032 75. Kakiuchi, N. & Ogawa, S. Clonal expansion in non-cancer tissues. *Nat. Rev. Cancer* 21, 239–
 1033 256 (2021).
- 1034 76. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
 1035 Preprint at https://doi.org/10.48550/arXiv.1303.3997 (2013).
- 1036 77. Sherry, S. T. *et al.* dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 29,
 1037 308–311 (2001).
- 1038 78. Zhang, F. *et al.* Ancestry-agnostic estimation of DNA sample contamination from sequence
 1039 reads. *Genome Res.* 30, 185–194 (2020).
- 1040 79. Danecek, P. et al. Twelve years of SAMtools and BCFtools. *GigaScience* 10, giab008 (2021).
- 1041 80. Subramanian, S. & Kumar, S. Neutral Substitutions Occur at a Faster Rate in Exons Than in

- 1042 Noncoding DNA in Primate Genomes. *Genome Res.* **13**, 838–844 (2003).
- 1043 81. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models Using
- 1044 lme4. J. Stat. Softw. 67, 1–48 (2015).
- 1045 82. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat. Genet.
- **47**, 1402–1407 (2015).
- 1047 83. Martinelli, S. et al. Molecular Diversity and Associated Phenotypic Spectrum of Germline
- 1048 CBL Mutations. *Hum. Mutat.* **36**, 787–796 (2015).
- 1049 84. Khadka, P. et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma
- 1050 formation. Nat. Commun. 13, 604 (2022).
- 1051 85. Frankish, A. et al. GENCODE 2021. Nucleic Acids Res. 49, D916–D923 (2021).
- 1052 86. The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic
- 1053 Acids Res. 51, D523–D531 (2023).
- 1054 87. Ou, J. & Zhu, L. J. trackViewer: a Bioconductor package for interactive and integrative
- 1055 visualization of multi-omics data. *Nat. Methods* **16**, 453–454 (2019).
- 1056 88. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).